Previous Page  15 / 24 Next Page
Information
Show Menu
Previous Page 15 / 24 Next Page
Page Background

Patients in both arms had received a

median of three prior systemic treatments.

According to investigator assessment,

treatment with mogamulizumab resulted

in a significant improvement in progres-

sion-free survival vs vorinostat (HR 0.53

[95% CI 0.41, 0.69], P < .0001) with a

median progression-free survival of 7.7

(95% CI 5.7, 10.3) months for mogamuli-

zumab and 3.1 (95% CI 2.9, 4.1) months for

vorinostat. Superiority of mogamulizumab

was confirmed by independent review.

Mogamulizumab was associated with

superior progression-free survival in pre-

defined subgroups as well.

Global overall response rate was

significantly improved in the patients ran-

domized to mogamulizumab at 28.0% vs

4.8% for vorinostat (P < .0001). Significant

improvement in the overall response

rate was found with mogmulizumab vs

vorinostat in patients with both mycosis

fungoides (21.0% vs 7.1%, respectively;

P = .0042) and Sézary syndrome (37.0%

vs 2.3%, respectively; P < .0001).

The overall response rate in predefined

subgroups, duration of response, and

response by disease compartment all

favored mogamulizumab vs vorinostat.

In addition, an overall response rate of

30.1% was observed in mogamulizumab-

treated patients who crossed over from

vorinostat.

Skindex-29 Symptoms Scale scores

demonstrated statistically significant

improvements in favor of mogamulizumab-

vs vorinostat-treated patients at cycles 3,

5, and 7 (P < .05).

Median duration to meaningful deteriora-

tion on the Skindex-29 Symptoms Scale

was 27.4 months for patients receiving

mogamulizumab vs 6.6 months for those

receiving vorinostat.

Median dose intensity for mogamulizumab

was 97.5% vs 95.7% for vorinostat, sup-

porting adequate treatment in both arms.

Treatment exposure was longer with mog-

amulizumab (median 170 vs 84 days for

vorinostat).

The most common treatment-emergent

adverse events (>20%) more frequent

(>15% difference) in the mogamulizumab

vs the vorinostat arm included infu-

sion-related reactions (33.2% vs 0.5%,

respectively) and drug-related skin erup-

tions (23.9% vs 0.5%, respectively).

The majority of treatment-emergent

adverse events with mogamulizumab

were mild to moderate in severity (grade

1/2, 54.9%; grade 3/4/5, 42.4%).

Dr. Kim concluded, “In this first report of

a randomized phase III study evaluating

progression-free survival as the primary

endpoint in cutaneous T-cell lymphoma,

the investigational monoclonal antibody

mogamulizumab demonstrated signifi-

cantly superior progression-free survival

overall response rate, and quality of life

vs vorinostat in patients with previously

treated cutaneous T-cell lymphoma.”

The safety profile was consistent with

previous reports.

www.practiceupdate.com/c/61491

© Todd Buchanan 2017, with permission by ASH

ASH 2017 • PRACTICEUPDATE CONFERENCE SERIES

15

© ELSEVIER COPYRIGHT